Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2007

01-04-2007 | Research Article

Self-reported medication and lifestyle adherence in Hungarian patients with Type 2 diabetes

Authors: Balázs Hankó, Margit Kázmér, Péter Kumli, Zsuzsanna Hrágyel, Antal Samu, Zoltán Vincze, Romána Zelkó

Published in: International Journal of Clinical Pharmacy | Issue 2/2007

Login to get access

Abstract

Background: Type 2 diabetes is a complex disorder that requires the patient to pay constant attention to diet, physical activity, glucose monitoring and medication.
Objective: To evaluate the medication, lifestyle adherence and factors associated to these in Type 2 diabetes in Hungarian patients.
Setting: Fourteen community pharmacies in Hungary between March and May 2004.
Method: A questionnaire was given to every tenth Type 2 diabetic patient who presented to one of the 14 pharmacies included in this study with a prescription for oral antidiabetics, oral antidiabetics and insulin or exclusively insulin. For the latter two groups, the prerequisite for inclusion in the study was also that their diabetes had developed after the age of 35 and that at some in their treatment regimen they had taken only oral antidiabetics. These latter two criteria were controlled in the patient's general practitioners' (GP) database. General and diabetes-related data were collected in the questionnaire, and the adherence and lifestyle of the participant were assessed. An adapted and validated Hungarian version of the EQ-5D (EuroQol Group, 1993) quality-of-life questionnaire was also included. Descriptive and χ2 test statistical methods and two sample t-test were used. A significance level of P<0.05 was considered to be significant.
Main outcome measure: Patient self-reported adherence to diet, physical activity, self monitoring of blood glucose, purchasing of drug(s), drug regimen, association of demographic factors, treatment, lifestyle and quality of life on adherence.
Results: Of the 220 questionnaires distributed to diabetic patients, 151 were returned, of which 142 were evaluated (nine did not satisfy the above-mentioned inclusion criteria). With respect to the factors assessed, sub-optimal adherence was assessed for: diet (76.8%), physical activity (33.8%), self-monitoring of blood glucose (81%), drug purchasing (20.4%) and drug taking (52.1%). Smokers comprised 14.8% of the respondents, while 8.5% were heavy drinkers. Fewer than five meals a day were eaten by 46.5% of the patients, and about 43.6% of the patients did not self-monitor blood glucose. The results indicate few significant associations between at least one of the four main areas of adherence (diet, physical activity, purchasing of drug(s), drug regimen) and body mass index, GP consultation frequency, quality-of-life parameters and EQ-5D index.
Conclusion: The adherence of Hungarian Type 2 diabetics in some areas does not reach optimal levels, especially for diet, self-monitoring, drug purchasing and adherence to drug taking.
Literature
1.
go back to reference Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease: a statement for health care professionals from the American Heart Association. Circulation 1999;100:1134–46PubMed Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. Diabetes and cardiovascular disease: a statement for health care professionals from the American Heart Association. Circulation 1999;100:1134–46PubMed
2.
go back to reference Glasgow RE. Compliance to diabetes regimens: conceptualization, complexity and determinants. In: Cramer JA, Spilker B, editor. Patient compliance in medical practice and clinical trials. New York: Raven Press; 1991 Glasgow RE. Compliance to diabetes regimens: conceptualization, complexity and determinants. In: Cramer JA, Spilker B, editor. Patient compliance in medical practice and clinical trials. New York: Raven Press; 1991
3.
go back to reference World Health Organization. Report on medication adherence. Geneva: World Health Org; 2003 World Health Organization. Report on medication adherence. Geneva: World Health Org; 2003
4.
go back to reference Rubin Richard R. Adherence to pharmacologic therapy in patients with Type 2 diabetes mellitus. Am J Med 2005;118:27S–34SPubMedCrossRef Rubin Richard R. Adherence to pharmacologic therapy in patients with Type 2 diabetes mellitus. Am J Med 2005;118:27S–34SPubMedCrossRef
5.
go back to reference Pugh MJ, Anderson J, Pogach LM, Berlowitz DR. Differential adoption of pharmacotherapy recommendations for Type 2 diabetes by generalists and specialists. Med Care Res Rev 2003;60:178–200PubMedCrossRef Pugh MJ, Anderson J, Pogach LM, Berlowitz DR. Differential adoption of pharmacotherapy recommendations for Type 2 diabetes by generalists and specialists. Med Care Res Rev 2003;60:178–200PubMedCrossRef
6.
go back to reference Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CT. Insulin omission in women with IDDM. Diabetes Care 1994;17:1178–83PubMed Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CT. Insulin omission in women with IDDM. Diabetes Care 1994;17:1178–83PubMed
7.
go back to reference Brown JB, Nichol GA, Glauber HS, Bakst A. Ten year follow up of antidiabetic drug use, non-adherence and mortality in a defined population with type 2 diabetes. Clin Ther 1999;21:1045–57PubMedCrossRef Brown JB, Nichol GA, Glauber HS, Bakst A. Ten year follow up of antidiabetic drug use, non-adherence and mortality in a defined population with type 2 diabetes. Clin Ther 1999;21:1045–57PubMedCrossRef
8.
go back to reference Johnson SB. Methodological issues in diabetes research: measuring adherence. Diabetes Care 1992;15:1658–67PubMed Johnson SB. Methodological issues in diabetes research: measuring adherence. Diabetes Care 1992;15:1658–67PubMed
9.
go back to reference Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch Med Res 2005;36:300–6PubMedCrossRef Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch Med Res 2005;36:300–6PubMedCrossRef
10.
go back to reference Glasgow RE, Toobert DJ, Gillette CD. Psychosocial barriers to diabetes self management and quality of life. Diabetes Spectrum 2001;14:33–41 Glasgow RE, Toobert DJ, Gillette CD. Psychosocial barriers to diabetes self management and quality of life. Diabetes Spectrum 2001;14:33–41
11.
go back to reference Cramer Joyce A. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–24PubMed Cramer Joyce A. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–24PubMed
12.
go back to reference Dezii Christopher M. Persistence with drug therapy: a practical approach using administrative claims data. Managed Care 2001;10:42–5 Dezii Christopher M. Persistence with drug therapy: a practical approach using administrative claims data. Managed Care 2001;10:42–5
13.
go back to reference Act LXIII of 1992 on the Protection of Personal Data and the Publicity of Data of Public Interest Act LXIII of 1992 on the Protection of Personal Data and the Publicity of Data of Public Interest
14.
go back to reference DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200–9PubMedCrossRef DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200–9PubMedCrossRef
15.
go back to reference Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–9PubMedCrossRef Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–9PubMedCrossRef
16.
go back to reference Koopmanschap M. CODE-2 Advisory Board. Coping with Type II diabetes: the patient’s perspective. Diabetologia 2002;45:S18–22PubMed Koopmanschap M. CODE-2 Advisory Board. Coping with Type II diabetes: the patient’s perspective. Diabetologia 2002;45:S18–22PubMed
17.
go back to reference Szende A, Nemeth R. Health-related quality of life of the Hungarian population. Orvosi Hetilap 2003;144:1667–74PubMed Szende A, Nemeth R. Health-related quality of life of the Hungarian population. Orvosi Hetilap 2003;144:1667–74PubMed
18.
go back to reference Szende A, Molnar L. General population-based quality of life measurements with the EQ-5D questionnaire. Value Health 2000;3:6–29 Szende A, Molnar L. General population-based quality of life measurements with the EQ-5D questionnaire. Value Health 2000;3:6–29
19.
go back to reference Badia X, Schiaffino A, Alonso J, Herdman M. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 1998;7:311–22PubMedCrossRef Badia X, Schiaffino A, Alonso J, Herdman M. Using the EuroQol 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 1998;7:311–22PubMedCrossRef
20.
go back to reference Ankri J, Beaufils B, Novella JL, Morrone I, Guillemin F, Jolly D, et al. Use of the EQ-5D among patients suffering from dementia. J Clin Epidemiol 2003;56:1055–63PubMedCrossRef Ankri J, Beaufils B, Novella JL, Morrone I, Guillemin F, Jolly D, et al. Use of the EQ-5D among patients suffering from dementia. J Clin Epidemiol 2003;56:1055–63PubMedCrossRef
21.
go back to reference Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, et al. Validity and reliability of the EQ-5D self-report questionnaire in English-speaking Asian patients with rheumatic diseases in Singapore. Qual Life Res 2003;12:87–92PubMedCrossRef Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH, et al. Validity and reliability of the EQ-5D self-report questionnaire in English-speaking Asian patients with rheumatic diseases in Singapore. Qual Life Res 2003;12:87–92PubMedCrossRef
22.
go back to reference Granja C, Teixeira-Pinto A, Costa-Pereira A. Quality of life after intensive care-evaluation with EQ-5D questionnaire. Intens Care Med 2002;28:898–907CrossRef Granja C, Teixeira-Pinto A, Costa-Pereira A. Quality of life after intensive care-evaluation with EQ-5D questionnaire. Intens Care Med 2002;28:898–907CrossRef
23.
go back to reference Burstrom K, Johannesson M, Dideichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621–35PubMedCrossRef Burstrom K, Johannesson M, Dideichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621–35PubMedCrossRef
24.
go back to reference The MHV Group. The measurement and valuation of health: Final report on the modeling of valuation tariffs. York: Centre for Health Economics, University of York; 1995 The MHV Group. The measurement and valuation of health: Final report on the modeling of valuation tariffs. York: Centre for Health Economics, University of York; 1995
25.
go back to reference Martin Bland. An introduction to medical statistics. Oxford: Oxford University Press; 1991 Martin Bland. An introduction to medical statistics. Oxford: Oxford University Press; 1991
26.
go back to reference Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761–73 Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761–73
27.
go back to reference Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-Monitoring of blood glucose among persons with diabetes. Diabetes Educ 2004;30:112–25PubMed Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-Monitoring of blood glucose among persons with diabetes. Diabetes Educ 2004;30:112–25PubMed
28.
go back to reference Anderson LA. Health-care communication and selected psychosocial correlates of adherence in diabetes management. Diabetes Care 1990;13:66–76 Anderson LA. Health-care communication and selected psychosocial correlates of adherence in diabetes management. Diabetes Care 1990;13:66–76
29.
go back to reference Hungarian Central Statistical Office (homepage on the Internet). Counted population 2004. Budapest, Hungarian Central Statistical Office (cited 18 Jul 2004). Available from: http//www.ksh.hu./ Hungarian Central Statistical Office (homepage on the Internet). Counted population 2004. Budapest, Hungarian Central Statistical Office (cited 18 Jul 2004). Available from: http//www.ksh.hu./
30.
go back to reference Hungarian Gallup Organization (homepage on the Internet). National Health Interview Survey Hungary. Hungarian Gallup Organization (cited 15 Jan 2005). Available from: http//www.gallup.hu./ Hungarian Gallup Organization (homepage on the Internet). National Health Interview Survey Hungary. Hungarian Gallup Organization (cited 15 Jan 2005). Available from: http//www.gallup.hu./
31.
go back to reference Shobhana R, Begum R, Snehalatha C, Vijay V, Ramachandran A. Patients’ adherence to diabetes treatment. J Assoc Physicians India 1999;47:1173–75PubMed Shobhana R, Begum R, Snehalatha C, Vijay V, Ramachandran A. Patients’ adherence to diabetes treatment. J Assoc Physicians India 1999;47:1173–75PubMed
32.
go back to reference Schultz JA, Sprague MA, Branen LJ, Lambeth S. A comparison of views of individuals with Type 2 diabetes mellitus and diabetes educators about barriers to diet and exercise. J Health Commun 2001;6:99–115CrossRef Schultz JA, Sprague MA, Branen LJ, Lambeth S. A comparison of views of individuals with Type 2 diabetes mellitus and diabetes educators about barriers to diet and exercise. J Health Commun 2001;6:99–115CrossRef
33.
go back to reference Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987;10:563–6PubMed Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987;10:563–6PubMed
34.
go back to reference Searle MS, Ready AE. Survey of exercise and dietary knowledge and behaviour in persons with Type II diabetes. Can J Public Health 1991;82:344–8PubMed Searle MS, Ready AE. Survey of exercise and dietary knowledge and behaviour in persons with Type II diabetes. Can J Public Health 1991;82:344–8PubMed
35.
go back to reference Swift CS, Armstrong JE, Beerman KA, Campbell RK, Pond-Smith D. Attitudes and beliefs about exercise among persons with non-insulin-dependent diabetes. Diabetes Educ 1995;21:533–40PubMed Swift CS, Armstrong JE, Beerman KA, Campbell RK, Pond-Smith D. Attitudes and beliefs about exercise among persons with non-insulin-dependent diabetes. Diabetes Educ 1995;21:533–40PubMed
36.
go back to reference Vincze G, Parthan A. The value of home monitoring kits in diabetes, hypertension, asthma, and oral anticoagulation therapy. J Pharm Pract 2004;17:182–96CrossRef Vincze G, Parthan A. The value of home monitoring kits in diabetes, hypertension, asthma, and oral anticoagulation therapy. J Pharm Pract 2004;17:182–96CrossRef
37.
go back to reference Patrick AW, Gill GV, MacFarlane IA, Cullen A, Power E, Wallymahmed M. Home glucose monitoring in Type 2 diabetes: is it a waste of time? Diabetes Med 1994;11:62–5 Patrick AW, Gill GV, MacFarlane IA, Cullen A, Power E, Wallymahmed M. Home glucose monitoring in Type 2 diabetes: is it a waste of time? Diabetes Med 1994;11:62–5
38.
go back to reference Gallichan M. Self monitoring of glucose by people with diabetes: evidence based practice. Br Med J 1997;314:964–7 Gallichan M. Self monitoring of glucose by people with diabetes: evidence based practice. Br Med J 1997;314:964–7
39.
go back to reference Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care 2000;23:477–83PubMed Karter AJ, Ferrara A, Darbinian JA, Ackerson LM, Selby JV. Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. Diabetes Care 2000;23:477–83PubMed
40.
go back to reference Anonymus. Many patients choose not to comply with prescribed medication regimens. Drug Benefit Trends 2004;16:107–8 Anonymus. Many patients choose not to comply with prescribed medication regimens. Drug Benefit Trends 2004;16:107–8
41.
go back to reference Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001;24:1411–15PubMed Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001;24:1411–15PubMed
42.
go back to reference Chiechhanowski PS, Katon WJ, Russo JE. Depression and diabetes. Arch Int Med 2000;160:3278–85CrossRef Chiechhanowski PS, Katon WJ, Russo JE. Depression and diabetes. Arch Int Med 2000;160:3278–85CrossRef
43.
go back to reference Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with Type 2 diabetes mellitus. Clin Ther 2001;23:1311–20PubMedCrossRef Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with Type 2 diabetes mellitus. Clin Ther 2001;23:1311–20PubMedCrossRef
44.
go back to reference Dezii Christopher M, Kawabata H, Tran M. Effects of once daily and twice daily dosing on adherence with prescribed glipizide oral therapy for Type 2 diabetes. South Med J 2002;95: 68–71PubMed Dezii Christopher M, Kawabata H, Tran M. Effects of once daily and twice daily dosing on adherence with prescribed glipizide oral therapy for Type 2 diabetes. South Med J 2002;95: 68–71PubMed
45.
go back to reference Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabet Med 2002;19:685–8PubMedCrossRef Evans JM, Donnan PT, Morris AD. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabet Med 2002;19:685–8PubMedCrossRef
46.
go back to reference Melikian C, White J, Vanderplas A, Dezii Christopher M, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24: 460–7PubMedCrossRef Melikian C, White J, Vanderplas A, Dezii Christopher M, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24: 460–7PubMedCrossRef
47.
go back to reference Morningstar BA, Sketirs IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by Type of oral antihyperglyceamic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002;27: 213–20PubMedCrossRef Morningstar BA, Sketirs IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by Type of oral antihyperglyceamic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002;27: 213–20PubMedCrossRef
48.
go back to reference Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015–21PubMed Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015–21PubMed
49.
go back to reference Spoelstra JA, Stolk RP, Heerdink ER, Klungel OH, Erkens JA, Leufkens HGM, et al. Refill compliance in Type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidem Drug Safe 2003;12:121–7CrossRef Spoelstra JA, Stolk RP, Heerdink ER, Klungel OH, Erkens JA, Leufkens HGM, et al. Refill compliance in Type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidem Drug Safe 2003;12:121–7CrossRef
50.
go back to reference Venturini F, Nichol MB, Sung JCY, Bailey KL, Cody M, McCombs JS. Compliance with sulfanylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999;33:281–8PubMedCrossRef Venturini F, Nichol MB, Sung JCY, Bailey KL, Cody M, McCombs JS. Compliance with sulfanylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999;33:281–8PubMedCrossRef
51.
go back to reference Peterson GM, McLean S, Senator GB. Determinants of patient compliance, control, presence of complications, and handicap in non-insulin-dependent diabetes. Aust N Z J Med 1984;14:135–41PubMed Peterson GM, McLean S, Senator GB. Determinants of patient compliance, control, presence of complications, and handicap in non-insulin-dependent diabetes. Aust N Z J Med 1984;14:135–41PubMed
52.
go back to reference Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with Type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958–71PubMedCrossRef Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with Type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958–71PubMedCrossRef
53.
go back to reference Winkler A, Teuscher AU, Mueller B, Diem P. Monitoring adherence to prescribed medication in Type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly 2002;132:379–85PubMed Winkler A, Teuscher AU, Mueller B, Diem P. Monitoring adherence to prescribed medication in Type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly 2002;132:379–85PubMed
54.
go back to reference Johnson KH, Bazargan M, Bing EG. Alcohol consumption and compliance among inner-city minority patients with Type 2 diabetes mellitus. Arch Fam Med 2000;9:964–70PubMedCrossRef Johnson KH, Bazargan M, Bing EG. Alcohol consumption and compliance among inner-city minority patients with Type 2 diabetes mellitus. Arch Fam Med 2000;9:964–70PubMedCrossRef
55.
go back to reference Wikby A, Hornquist JO, Andersson PO. Background, quality of life and metabolic control in patients with insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1991;13:53–61PubMedCrossRef Wikby A, Hornquist JO, Andersson PO. Background, quality of life and metabolic control in patients with insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1991;13:53–61PubMedCrossRef
56.
go back to reference Eiser C, Flynn M, Green E, Havermans T, Kirby R, Sanderman D, et al. Quality of life in young adults with Type 1 diabetes in relation to demographic and disease variables. Diabetes Med 1992;9:375–8CrossRef Eiser C, Flynn M, Green E, Havermans T, Kirby R, Sanderman D, et al. Quality of life in young adults with Type 1 diabetes in relation to demographic and disease variables. Diabetes Med 1992;9:375–8CrossRef
57.
go back to reference Piette JD, Heisler M, Wagner TH. Problems paying out-of-packet medication costs among older adults with diabetes. Diabetes Care 2004;27:384–91PubMed Piette JD, Heisler M, Wagner TH. Problems paying out-of-packet medication costs among older adults with diabetes. Diabetes Care 2004;27:384–91PubMed
58.
go back to reference Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 2003;26:3054–60PubMed Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 2003;26:3054–60PubMed
59.
go back to reference Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626–34PubMedCrossRef Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626–34PubMedCrossRef
60.
go back to reference Blenkinsopp A, Hassey A. Effectiveness and acceptability of community pharmacy-based interventions in type 2 diabetes: a critical review of intervention design, pharmacist and patient perspectives. Int J Pharm Pract 2005;13:231–40CrossRef Blenkinsopp A, Hassey A. Effectiveness and acceptability of community pharmacy-based interventions in type 2 diabetes: a critical review of intervention design, pharmacist and patient perspectives. Int J Pharm Pract 2005;13:231–40CrossRef
61.
go back to reference Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next? J Allergy Clin Immunol 2003;112:489–94PubMedCrossRef Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next? J Allergy Clin Immunol 2003;112:489–94PubMedCrossRef
Metadata
Title
Self-reported medication and lifestyle adherence in Hungarian patients with Type 2 diabetes
Authors
Balázs Hankó
Margit Kázmér
Péter Kumli
Zsuzsanna Hrágyel
Antal Samu
Zoltán Vincze
Romána Zelkó
Publication date
01-04-2007
Publisher
Kluwer Academic Publishers
Published in
International Journal of Clinical Pharmacy / Issue 2/2007
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-006-9070-2

Other articles of this Issue 2/2007

International Journal of Clinical Pharmacy 2/2007 Go to the issue